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the STOP-NIDDM trial was developed to replicate the manage-
ment of IGT patients over the 3.3-year trial period. The cost-
effectiveness measures were cost per patient free of diabetes and
cost per month free of diabetes. Analyses were performed for the
total trial population and three subgroups: high risk for diabetes,
high risk for CV disease and high risk for combined diabetes-CV
disease. Total direct costs were calculated using standard sources
and published literature. Costs and outcomes were discounted 
at 3% and extensive sensitivity analyses were conducted.
RESULTS: The incremental cost per patient free of diabetes
(month free of diabetes) was 3032€ (136€) and 829€ (35€) 
for the total study population and high risk diabetes sub-
group respectively. Acarbose treatment dominated (i.e. was 
more effective, less costly) placebo in subgroups at high CV 
risk and high combined diabetes-CV risk. Deterministic sensi-
tivity analyses showed that the discount rate for costs and the
probability of transition to diabetes had the largest impact on
results. CONCLUSIONS: Acarbose treatment signiﬁcantly
reduces the incidence of diabetes and CV events in IGT patients.
This clinical advantage is expected to lead to reductions in
healthcare costs that exceed the acquisition cost of acarbose, thus
resulting in overall cost savings in high risk subgroups for CV
disease and combined diabetes-CV disease. For the total study
population and the high risk diabetes subgroup, savings from
fewer cases of diabetes and CV events partly offset the cost of
acarbose.
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OBJECTIVE: To estimate the cost of intensive treatment of DM
T2patients (insulin therapy and combined treatment with insulin
and oral hypoglycemic agents (OHAs)). METHODS: The study
was conducted for 24 weeks and included 4 visits. In total, 153
patients in DM T2 were examined (65% women and 35% men).
The average age was 56.7 years, the duration of the disease was
9.5 years. The cost of treatment included: the cost of patient
observation, daily test monitoring, diagnostic manipulations and
consultations and cost of the medicines used. Analysis of expen-
ditures was conducted using the incremental cost estimation
method that takes into account only the changing quantities.
RESULTS: All the patients were divided into two groups in
dependence on the result obtained: group 1 (85pts.), with a level
of HbA1c < or = 7.0%, and group 2 (68pts.), with a level of
HbA1c > 7% (p = 0.2784). In group 1, 60 patients received
insulin monotherapy and 25—a combination of insulins and
OHAs. In group 2, these subgroups counted 34 and 34 patients,
respectively. The intensive treatment was associated with
increases in the patient management costs by USD 0.89/patient
in group 1 and USD 0.78/patient group 2. The cost of treatment
increased because of an increase in the consumption of insulin
and expenditures on intensive observation. CONCLUSION:
The cost of achieving the clinical efﬁcacy criteria in the group
where optimal glycemic control was achieved turned out to be
comparable with the cost of managing patients in the group
where this control was not achieved. However, in group 1, a
decrease in the cost of treatment of concurrent diseases was
noted. Thus, proof was obtained: glycemic control is the major
determinant of the development of cardiovascular complications
of advanced DM.
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OBJECTIVES: Various delivery systems for inhaled insulin (INI)
are under development. However, they will likely be substantially
more expensive than subcutaneous insulin (SCI). Whether this
increased cost is justiﬁed is an important question which can be
addressed through Contingent Valuation (CV), a survey tech-
nique that elicits individuals’ preferences for non-marketed prod-
ucts in terms of the amount they would be willing-to-pay. The
purpose of this study was to assess diabetic (DM) patients’ pref-
erence and willingness-to-pay (WTP) for INI. METHODS: A
face-to-face CV survey was administered to 96 type-1 and type-
2 adult DM patients at St. Michael’s Hospital (Toronto, Canada)
who were taking insulin and/or oral antihyperglycaemic drugs.
Standardized information about INI and SCI was provided by
video, and participant’s WTP was elicited using “payment scale”
method, along with socioeconomic and clinical data. Published
data was used to deﬁne INI attributes. The CV questionnaire
received expert review for content validity and was pilot tested
with 22 patients. RESULTS: Participants were 51.8 ± 13.4 years
old, and had DM for an average of 11.8 ± 7.8 years; 77 had
type-2 and 19 had type-1 DM. Signiﬁcantly more participants
(89%) preferred INI over SCI (P < 0.01). The mean monthly
WTP for INI ($153.70 ± $99.90) was signiﬁcantly more than
typical SCI cost of $50 (P < 0.01). A greater proportion of type-
2 patients (n = 72/77) preferred INI than did type-1 patients 
(P < 0.001). The mean WTP for INI in type-2 subgroup ($177.10
± $91.60) was signiﬁcantly more compared to type-1 ($154 ±
$66.6, P = 0.025). Signiﬁcantly more participants who were not
on insulin preferred INI compared to participants using insulin
(P < 0.001). Multiple-regression analysis showed strong associ-
ation between participants’ income and insulin experience and
their WTP for INI (P < 0.001). CONCLUSIONS: DM patients
prefer INI over SCI and are willing-to-pay signiﬁcantly more per
month than the cost of SCI. Preferences are stronger in type-1
patients DM and those with prior insulin experience.
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OBJECTIVES: Type-2 diabetes mellitus is a chronic and pro-
gressive disease with a negative impact on quality of life. Objec-
tives of the present study were to describe Health-Related
Quality of life (HRQOL) in type-2 diabetes mellitus and to
compare the health state between diabetic and non-diabetic sub-
jects. METHODS: Type-2 diabetes mellitus patients were
selected from a representative sample of the Italian general pop-
ulation aged from 40 to 79 years enrolled in a population based
naturalistic prospective survey. We matched each of them by age
and sex with a non-diabetic subjects. The EuroQoL (EQ-5D), a
self-administered generic questionnaire, completed during the
enrolment visit, was used to evaluate HRQOL. RESULTS: We
analyzed two groups of 157 subjects each (diabetic and non-
diabetic group). The mean age was 63.0 years, 94 (59.9) were
male. Diabetic patients reported more problems than non-
diabetic subjects in the physical sphere, speciﬁcally for mobility
